Nkarta Therapeutics Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Public

  • Employees
  • 103

Employees

  • Stock Symbol
  • NKTX

Stock Symbol

  • Share Price
  • $1.14
  • (As of Friday Closing)

Nkarta Therapeutics General Information

Description

Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 1150 Veterans Boulevard
  • South San Francisco, CA 94080
  • United States
+1 (925)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 1150 Veterans Boulevard
  • South San Francisco, CA 94080
  • United States
+1 (925)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Nkarta Therapeutics Stock Performance

As of 20-Nov-2026, Nkarta Therapeutics’s stock price is $1.14. Its current market cap is $81.3M with 71.6M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.14 $1.12 $1.10 - $3.72 $81.3M 71.6M 1.02M -$1.73

Nkarta Therapeutics Financials Summary

As of 30-Sep-2026, Nkarta Therapeutics has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 78,432 (74,292) (21,890) 137,729
Revenue 0 0 0 0
EBITDA (130,467) (110,378) (118,907) (125,708)
Net Income (128,935) (104,084) (108,790) (117,501)
Total Assets 308,461 404,209 501,203 378,885
Total Debt 72,037 76,420 80,273 88,339
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Nkarta Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Nkarta Therapeutics‘s full profile, request access.

Request a free trial

Nkarta Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Nkarta Therapeutics‘s full profile, request access.

Request a free trial

Nkarta Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf enginee
Biotechnology
South San Francisco, CA
103 As of 2026

San Diego, CA
 

South San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Nkarta Therapeutics Competitors (35)

One of Nkarta Therapeutics’s 35 competitors is Fate Therapeutics, a Formerly VC-backed company based in San Diego, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Fate Therapeutics Formerly VC-backed San Diego, CA
Lyell Immunopharma Formerly VC-backed South San Francisco, CA
Aura Biosciences Formerly VC-backed Boston, MA
ArsenalBio Venture Capital-Backed South San Francisco, CA
Arvinas Formerly VC-backed New Haven, CT
You’re viewing 5 of 35 competitors. Get the full list »

Nkarta Therapeutics Patents

Nkarta Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026112371-A2 Modulation of immune cell gene expression Pending 25-Nov-2024
WO-2026112371-A3 Modulation of immune cell gene expression Pending 25-Nov-2024
US-20260144874-A1 Compositions for treatment of autoimmune diseases Pending 09-Oct-2024
WO-2026080586-A1 Compositions for treatment of autoimmune diseases Pending 09-Oct-2024
WO-2025171147-A1 Transmembrane proteins and related compositions and uses Pending 09-Feb-2024 C07K14/5443
To view Nkarta Therapeutics’s complete patent history, request access »

Nkarta Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Nkarta Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Nkarta Therapeutics‘s full profile, request access.

Request a free trial

Nkarta Therapeutics ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

37.76 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Nkarta Therapeutics’s complete esg history, request access »

Nkarta Therapeutics FAQs

  • When was Nkarta Therapeutics founded?

    Nkarta Therapeutics was founded in 2015.

  • Where is Nkarta Therapeutics headquartered?

    Nkarta Therapeutics is headquartered in South San Francisco, CA.

  • What is the size of Nkarta Therapeutics?

    Nkarta Therapeutics has 103 total employees.

  • What industry is Nkarta Therapeutics in?

    Nkarta Therapeutics’s primary industry is Biotechnology.

  • Is Nkarta Therapeutics a private or public company?

    Nkarta Therapeutics is a Public company.

  • What is Nkarta Therapeutics’s stock symbol?

    The ticker symbol for Nkarta Therapeutics is NKTX.

  • What is the current stock price of Nkarta Therapeutics?

    As of 20-Nov-2026 the stock price of Nkarta Therapeutics is $1.14.

  • What is the current market cap of Nkarta Therapeutics?

    The current market capitalization of Nkarta Therapeutics is $81.3M.

  • Who are Nkarta Therapeutics’s competitors?

    Fate Therapeutics, Lyell Immunopharma, Aura Biosciences, ArsenalBio, and Arvinas are some of the 35 competitors of Nkarta Therapeutics.

  • What is Nkarta Therapeutics’s annual earnings per share (EPS)?

    Nkarta Therapeutics’s EPS for 12 months was -$1.73.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process